European Journal of Medicinal Chemistry p. 350 - 366 (2019)
Update date:2022-08-05
Topics:
Yin, Huanhuan
Dong, Jingjing
Cai, Yingchun
Shi, Ximeng
Wang, Hao
Liu, Guixia
Tang, Yun
Liu, Jianwen
Ma, Lei
Overexpression of P-glycoprotein (P-gp) is one of the major causes for multidrug resistance (MDR), which has become a major obstacle in cancer therapy. One hopeful approach to reverse the MDR is to develop inhibitors of P-gp in expression and/or function. Here, we designed and synthesized a series of chalcone derivatives as P-gp inhibitors and evaluated their potential reversal activities against MDR. Among them, the most active compound MY3 had little intrinsic cytotoxicity and showed the highest activity (RF = 50.19) in reversing DOX resistance in MCF-7/DOX cells. Further studies demonstrated that MY3 could increase intracellular accumulation of DOX and inhibit expression of P-gp at mRNA and protein levels. More importantly, MY3 significantly enhanced the efficacy of DOX against the tumor xenografts bearing MCF-7/DOX cells with the precondition of unchanged body weight. Therefore, MY3 might represent a promising lead to develop MDR reversal agents for cancer chemotherapy.
View MoreHangzhou Deli Chemical Co.,Ltd.
website:http://www.dlchemical.com
Contact:86 571 28006267
Address:Tangxi Industrial Area, Yuhang District, Hangzhou
Nanjing lanbai chemical Co.,Ltd.
Contact:+86-25-85499326
Address:Room 908, 9F Taiyue Building,No.285 Heyan Road
Contact:+86-15850770348
Address:51 OF XIANGFANGCUN ROAD, Nanjing 210002, China
Contact:+86-10-59484199
Address:No.58-A1026 Liangguan Street
Hubei Sky Lake Chemical Co., Ltd.
Contact:+86-27-87385545
Address:Te-2, Xijiao Chemical Park, Yuekou Town, Tianmen, Hubei, China.
Doi:10.1021/jo01340a052
(1966)Doi:10.1002/jhet.2625
(2017)Doi:10.1016/S0960-894X(03)00127-6
(2003)Doi:10.1021/jo01334a009
(1979)Doi:10.1021/ja00508a042
(1979)Doi:10.1016/j.jorganchem.2004.02.025
(2004)